Nursing facility
Gardena Hospital LP
Gardena Hospital LP was paid $15.36M by Medicaid between Jan 2018 and Dec 2024, across 226 billing codes. Its largest line is 0450, Emergency room services — 23% of everything it billed.
33Billing provider infoGARDENA HOSPITAL LP
GARDENA, CA 90247
GARDENA, CA 90247
33aNPI1063412005assigned 07/29/2005
33bProvider typeSkilled Nursing Facility
28Total paid$15.36M
24GClaims656,867
24DCodes billed226
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Skilled Nursing Facility providers in California
Rank by total paid#8 of 547
Median peer was paid$73K
This provider vs. median210×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 110,060 | $2.16M | |
| 2019 | 94,062 | $3.06M | |
| 2020 | 72,454 | $1.50M | |
| 2021 | 78,208 | $1.74M | |
| 2022 | 97,677 | $2.34M | |
| 2023 | 111,449 | $2.60M | |
| 2024incomplete | 92,957 | $1.96M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 23% | 88,010 | 79,775 | $3.59M |
| 70450 | Computed tomography, head or brain; without contrast material | 5.2% | 7,834 | 7,571 | $803K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.2% | 16,758 | 15,607 | $794K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 5.0% | 12,045 | 10,417 | $771K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 4.0% | 6,430 | 6,238 | $607K |
| Z7502 | 2.8% | 11,456 | 11,196 | $424K | |
| 94642 | 2.7% | 4,257 | 4,041 | $413K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.5% | 13,048 | 12,192 | $385K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.4% | 1,979 | 1,907 | $369K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.1% | 16,708 | 15,879 | $330K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 5,543 | 5,353 | $319K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.0% | 4,873 | 4,613 | $313K |
214 more codes
| 80053 | Comprehensive metabolic panel | 1.8% | 28,045 | $274K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 10,808 | $259K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 6,739 | $244K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.5% | 12,206 | $238K |
| 99199 | Unlisted special service, procedure or report | 1.5% | 6,123 | $228K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 38,351 | $223K |
| J3490 | Unclassified drugs | 1.3% | 17,992 | $202K |
| 99283 | Emergency room visit (moderate) | 1.3% | 3,914 | $197K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 14,346 | $172K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 1,029 | $168K |
| 0121 | 1.1% | 96 | $165K | |
| 93970 | 1.1% | 1,041 | $165K | |
| 76801 | <1% | 2,975 | $144K | |
| 0360 | <1% | 1,896 | $140K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,047 | $131K |
| 0636 | <1% | 9,143 | $130K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,435 | $118K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 869 | $107K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,346 | $106K |
| 0250 | <1% | 18,335 | $98K | |
| 83880 | <1% | 5,008 | $96K | |
| 84484 | <1% | 12,227 | $94K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,210 | $94K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,230 | $90K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,628 | $85K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,065 | $83K |
| 0270 | <1% | 10,000 | $74K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,892 | $72K |
| 81025 | <1% | 15,956 | $68K | |
| 83690 | <1% | 13,105 | $68K | |
| 70486 | <1% | 607 | $66K | |
| 87040 | <1% | 4,458 | $66K | |
| 0710 | <1% | 1,982 | $61K | |
| 0272 | <1% | 3,800 | $53K | |
| 0206 | <1% | 69 | $50K | |
| 85730 | <1% | 9,293 | $45K | |
| 83605 | <1% | 5,284 | $44K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,095 | $43K |
| 84702 | <1% | 3,567 | $41K | |
| 81003 | <1% | 21,982 | $40K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,656 | $39K |
| Z7500 | <1% | 1,135 | $39K | |
| 71250 | <1% | 315 | $37K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,796 | $37K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,396 | $37K |
| Z7610 | <1% | 2,645 | $36K | |
| 0720 | <1% | 310 | $36K | |
| 0300 | <1% | 717 | $36K | |
| 85610 | <1% | 9,836 | $35K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,974 | $32K |
| 73610 | <1% | 1,466 | $30K | |
| 73562 | <1% | 1,416 | $29K | |
| 0510 | <1% | 1,570 | $29K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 601 | $29K |
| 73130 | <1% | 1,400 | $29K | |
| 0762 | <1% | 90 | $28K | |
| 73030 | <1% | 1,424 | $27K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 125 | $27K |
| 94760 | <1% | 3,803 | $27K | |
| 73630 | <1% | 1,244 | $25K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,127 | $24K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,973 | $24K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 424 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,041 | $23K |
| 81001 | <1% | 6,733 | $20K | |
| 90715 | <1% | 689 | $20K | |
| 76377 | <1% | 889 | $19K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 140 | $19K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 975 | $19K |
| 96368 | <1% | 1,103 | $19K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,168 | $19K |
| 99406 | <1% | 1,966 | $18K | |
| 74018 | <1% | 1,325 | $18K | |
| 72131 | <1% | 165 | $18K | |
| 82948 | <1% | 5,720 | $17K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,691 | $16K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,928 | $16K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,385 | $15K |
| 72110 | <1% | 471 | $15K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 65 | $14K |
| 80320 | <1% | 4,940 | $14K | |
| 73110 | <1% | 595 | $12K | |
| 85027 | <1% | 2,501 | $12K | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 156 | $12K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,930 | $12K |
| 87077 | <1% | 1,964 | $11K | |
| 87186 | <1% | 1,408 | $11K | |
| 59025 | Fetal non-stress test | <1% | 647 | $11K |
| Z6410 | <1% | 713 | $10K | |
| V2632 | Posterior chamber intraocular lens | <1% | 29 | $10K |
| 99221 | <1% | 349 | $9K | |
| 86901 | <1% | 3,433 | $9K | |
| 0370 | <1% | 124 | $9K | |
| 82553 | <1% | 950 | $9K | |
| A4649 | Surgical supply; miscellaneous | <1% | 3,197 | $8K |
| 73564 | <1% | 381 | $8K | |
| 96376 | <1% | 1,302 | $7K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,624 | $7K |
| 80329 | <1% | 2,173 | $7K | |
| 81005 | <1% | 4,088 | $7K | |
| 85007 | <1% | 2,475 | $6K | |
| Z9725 | <1% | 193 | $6K | |
| 36573 | <1% | 29 | $6K | |
| 82550 | <1% | 1,057 | $5K | |
| 0760 | <1% | 1,248 | $5K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 372 | $5K |
| 0255 | <1% | 531 | $5K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,272 | $4K |
| 84703 | <1% | 754 | $4K | |
| J1815 | Injection, insulin, per 5 units | <1% | 745 | $4K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 250 | $4K |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 883 | $4K |
| 0271 | <1% | 404 | $4K | |
| 81002 | <1% | 1,133 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,436 | $4K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 836 | $4K |
| 0761 | <1% | 168 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 76 | $4K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 913 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 553 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 902 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 379 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 912 | $3K |
| 87400 | <1% | 736 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 77 | $3K |
| 0160 | <1% | 49 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 946 | $3K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 41 | $3K |
| 73502 | <1% | 148 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 807 | $3K |
| 86850 | <1% | 680 | $3K | |
| 85379 | <1% | 358 | $3K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 146 | $3K |
| 29125 | <1% | 93 | $2K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 322 | $2K |
| 76830 | Ultrasound, transvaginal | <1% | 57 | $2K |
| Z7514 | <1% | 38 | $2K | |
| J3486 | Injection, ziprasidone mesylate, 10 mg | <1% | 104 | $2K |
| 0750 | <1% | 15 | $2K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 483 | $2K |
| 82009 | <1% | 676 | $2K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,173 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 535 | $2K |
| 73080 | <1% | 94 | $2K | |
| 86900 | <1% | 758 | $2K | |
| 12001 | <1% | 102 | $2K | |
| 10060 | <1% | 102 | $1K | |
| H1003 | Prenatal care, at-risk enhanced service; education | <1% | 297 | $1K |
| 94799 | <1% | 159 | $1K | |
| 12002 | <1% | 45 | $1K | |
| 71101 | <1% | 52 | $1K | |
| 12011 | <1% | 54 | $1K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 17 | $1K |
| 82140 | <1% | 116 | $889.67 | |
| 73090 | <1% | 51 | $838.89 | |
| 86703 | <1% | 56 | $834.83 | |
| 76937 | <1% | 68 | $828.45 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 70 | $818.16 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 206 | $798.39 |
| 82803 | <1% | 39 | $788.47 | |
| 71020 | <1% | 32 | $780.00 | |
| 76775 | <1% | 26 | $753.14 | |
| 73140 | <1% | 71 | $708.66 | |
| 0301 | <1% | 319 | $697.72 | |
| 72050 | <1% | 27 | $688.14 | |
| 80061 | Lipid panel | <1% | 100 | $655.73 |
| 83735 | <1% | 176 | $647.78 | |
| 76857 | <1% | 24 | $623.52 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 31 | $618.63 |
| 73590 | <1% | 41 | $605.45 | |
| 86328 | <1% | 28 | $572.09 | |
| 51798 | <1% | 13 | $529.91 | |
| 36569 | <1% | 15 | $523.64 | |
| 0324 | <1% | 182 | $487.67 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 148 | $485.59 |
| 0004A | <1% | 12 | $480.00 | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 15 | $465.15 |
| Z6406 | <1% | 34 | $434.18 | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 16 | $420.23 |
| 87807 | <1% | 62 | $384.75 | |
| 71010 | <1% | 23 | $342.47 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 57 | $339.77 |
| 99070 | <1% | 114 | $332.31 | |
| 86769 | <1% | 22 | $322.70 | |
| Z6400 | <1% | 16 | $313.65 | |
| 0451 | <1% | 12 | $313.19 | |
| V5008 | Hearing screening | <1% | 13 | $313.03 |
| 87081 | <1% | 47 | $306.11 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 100 | $280.41 |
| 85008 | <1% | 182 | $204.09 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 52 | $194.86 |
| 94644 | <1% | 12 | $165.33 | |
| 80185 | <1% | 17 | $161.50 | |
| 88304 | <1% | 43 | $145.77 | |
| 29130 | <1% | 25 | $122.28 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 26 | $118.67 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 39 | $116.50 |
| A4628 | Oral and/or oropharyngeal suction catheter, each | <1% | 91 | $104.27 |
| 87339 | <1% | 14 | $98.14 | |
| 87280 | <1% | 15 | $96.82 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 175 | $96.48 |
| 87430 | <1% | 16 | $91.49 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 14 | $65.30 |
| 87210 | <1% | 24 | $58.10 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 24 | $45.54 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 14 | $20.86 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 13 | $6.42 |
| 99072 | <1% | 29 | $0.01 | |
| 0302 | 0% | 201 | $0.00 | |
| 0730 | 0% | 155 | $0.00 | |
| 0402 | 0% | 13 | $0.00 | |
| 0320 | 0% | 12 | $0.00 | |
| 0460 | 0% | 45 | $0.00 | |
| 0424 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMACPHERSON, JAMES (OWNER)
| Provider | Location | Paid |
|---|---|---|
| CHHP Holdings II, LLC | Huntington Park, CA | $17.21M |
| Eladh, LP | Los Angeles, CA | $5.38M |
| CPH Hospital Management LLC | Norwalk, CA | $3.68M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.